NasdaqCM - Delayed Quote ? USD Titan Pharmaceuticals, Inc. (TTNP) Follow Compare 4.0049 +0.0149 (+0.37%) At close: November 1 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd. NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”). The Merger Agreement was approved by Titan’s board of directors (the “Board”). If the Merger Agreement is approved by the stockholders of Titan and KE (and the other closing conditions are satisfied or waived in accordance GlobeNewswire ? 2 months ago TTNP +0.37% TTNPW Titan Pharmaceuticals: Q2 Earnings Snapshot SAN FRANCISCO (AP) — Titan Pharmaceuticals Inc. TTNP) on Thursday reported a loss of $2.1 million in its second quarter. On a per-share basis, the San Francisco-based company said it had a loss of $2.29. Associated Press Finance ? 2 months ago TTNPW Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that by letter dated January 24, 2024, the Company was notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1.00 bid price requirement and otherwise satisfies all applicable criteria for continued listing on The Nasdaq Capital Market. As such, the listing matter has been closed. About Titan Pharmaceutica GlobeNewswire ? 9 months ago TTNP +0.37% TTNPW Titan Pharmaceuticals Announces Reverse Stock Split and Ratio SOUTH SAN FRANCISCO, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock, which will be effective following the filing of an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”). The Company's stockholders approved the reverse stock split at a Special Meeting of Stockholders on D GlobeNewswire ? 9 months ago TTNP +0.37% TTNPW Performance Overview Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return TTNP S&P 500 YTD -51.16% +20.10% 1-Year -49.94% +36.60% 3-Year -88.36% +24.39%
